Business Overview and Strategy

Management described Arvaya as a technology-led healthcare company founded on the premise of using data and technology to deliver better healthcare at an affordable cost. The company's core strategy involves creating a lifetime digital health record for patients (a "digital health briefcase") and developing an AI-powered clinical intelligence engine to support clinical decisions. The long-term vision is to build an integrated Health Managed Organization (HMO) inspired by the Kaiser Permanente model, excluding the insurance component.

The company's three key building blocks are:

1. Hospitals: Delivery channel through SeCURE Hospitals, a 100% subsidiary.

2. ArvayaSecure App: A patient app for health records, appointments, teleconsultation, diagnostics, and pharmacy.

3. Clinical Intelligence Engine (SecurANT): An AI engine to turn medical records into structured data and support doctor decisions.

Operational Performance (Q2 & H1 FY27)

Capacity & Utilization:

  • Operational beds stood at 517 as of September 2026, up from 262 a year ago.
  • Overall occupancy was 38% (Q2 FY27), compared to 48% a year ago. The decline is attributed to the near-doubling of the bed base, with established hospitals running at 46% occupancy and newer hospitals at 27%.
  • Patient discharges grew 38% year-on-year to 5,526 in Q2 FY27.
  • Outpatient (OPD) visits increased to 35,429 in Q2 FY27 from 33,500 previously.
  • Average Revenue Per Occupied Bed (ARPOB) rose approximately 17% year-on-year to ₹23,651, driven by a richer case mix in specialties like cardiology, neurosciences, kidney, and robotic surgery.

Hospital Specifics:

  • Hubballi (flagship, 135 beds across two units) ran at 56.5% occupancy in H1.
  • Mysuru-II hospital, added in August, has the highest ARPOB at ₹31,000.
  • Kolhapur hospital broke even in its first month of operation.
  • The company follows an asset-light model, with all operating units except Gadag being leased.

Financial Performance

Q2 FY27 Financials:

  • Revenue: ₹40 Crore, up 35% quarter-on-quarter (QoQ).
  • EBITDA: ₹5.24 Crore, up 32% QoQ.
  • EBITDA Margin: 13.0% (vs. 13.1% in Q1 FY27).
  • Profit After Tax (PAT): ₹1.37 Crore, up from ₹0.53 Crore in Q1 FY27 (158% growth QoQ).
  • Earnings Per Share (EPS): ₹0.25.

H1 FY27 Financials:

  • Revenue: ₹70.19 Crore.
  • EBITDA: ₹9.21 Crore.
  • EBITDA Margin: 13.1%.
  • Profit After Tax (PAT): ₹1.9 Crore.

Balance Sheet & Cash Flow (as of September 30, 2026):

  • Equity: ₹63.96 Crore.
  • Borrowings: ₹31.34 Crore.
  • Cash: ₹2.8 Crore.
  • Net Debt: ₹28.54 Crore (approx. 0.45x equity).
  • Operating Cash Flow (H1): ₹8.6 Crore (89% of EBITDA).

Expansion and Growth Plans

Near-term Capacity:

  • The company expects to have 791 operational beds by December 2026. This includes the integration of Sushodha Institute of Gastroenterology (SIGPL), effective November 1, 2026.
  • Of the 791 beds, 517 are currently operating, meaning 274 beds are under fit-outs and expected to be operational in Q3 FY27.

Signed Pipeline:

  • MoUs signed for 220 beds in Jalna, Sangli, and Shivamogga, due to be operational by the end of FY28.

Long-term Target:

  • Targeting 2,400 beds by FY30 through operating partnerships and acquisitions.

Recent Acquisition - Sushodha Institute of Gastroenterology (SIGPL):

  • Acquired via a 100% share swap deal with no cash payout.
  • It is a super-specialty gastroenterology unit.
  • Current run rate: ~₹1 Crore monthly revenue.
  • Expected profitability: ~15-18%.
  • Expected contribution by March 2027: ~₹5 Crore turnover and ~₹70-80 Lakh profit.

Technology Initiatives

ArvayaSecure App:

  • The patient engagement app is scheduled to be launched in the current financial year (FY27).
  • 30,000 historical patient records have already been ingested and are enabled on the platform.
  • The app will be fully deployed across the SeCURE network by next quarter (Q3 FY27).

Clinical Intelligence Engine (SecurANT):

  • The AI engine is at the pilot stage and is already working on the 30,000 ingested patient records.
  • Built on global FHIR standards.

Funding for Tech: A proposed rights issue of ₹206 Crore includes an earmarked ₹4.5 Crore for further development of SecurANT. Annual running costs are estimated at ₹2-3 Crore.

Future Business Lines

Management expressed intent to build a diagnostic network (labs and home collection services) and radiology services to feed data into their technology platform and support the HMO vision. A formal plan is expected to be discussed next quarter.

Capital Expenditure & Funding

Capex Model: A new 100-bed hospital in a leased building costs approx. ₹23.6 Crore to set up and is planned to break even in 1.5-2 years.

Rights Issue: The company has filed for a rights issue of ₹206 Crore to fund new medical equipment, fit-outs, and planned acquisitions.

Guidance and Outlook

  • EBITDA margins are expected to be sustainable in the range of 13-14% going forward.
  • The company aims to hold EBITDA broadly at current levels during expansion, as new beds are expected to reach breakeven over a short period.

Other Key Disclosures

Goa Resort: The property is being repurposed for wellness, with current occupancy being negligible. Work is ongoing, and details on occupancy and margins (expected 15-20%) are anticipated next quarter.

Government Schemes: Revenue from schemes like Ayushman Bharat constitutes 15-20% of the mix. They aid in utilization but are less profitable than private payers.

Geographic Focus: The company will initially focus on saturating 12-15 core districts in Karnataka and Maharashtra to build a concentrated regional network essential for its HMO model before expanding to other regions.

Data Security: The technology architecture is built to be compliant with global standards like HIPAA and India's DPDP Act from the ground up.